




RealRate

PHARMACEUTICAL 2024

Monopar Therapeutics
Rank 154 of 309



The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Monopar Therapeutics is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 63% points.

The company's Economic Capital Ratio, given in the ranking table, is 216%, being 3.1% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	7,333
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,757
Liabilities, Non-Current	0
Other Assets	13
Other Compr. Net Income	-23
Other Expenses	0
Other Liabilities	0
Other Net Income	429
Other Revenues	0
Property and Equipment	0
Research and Development	5,600
Selling, General and Administrative Expense	3,231

Output Variable	Value in 1000 USD
Assets	7,345
Liabilities	1,757
Expenses	8,831
Revenues	0
Stockholders Equity	5,588
Net Income	-8,402
Comprehensive Net Income	-8,414
BaseVar	9,193
ECR before LimitedLiability	83%
Economic Capital Ratio	216%